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1. INTRODUCTION {#dmrr3015-sec-0005}
===============

Glycaemic control is one of the primary goals of clinical management for most patients with diabetes.[1](#dmrr3015-bib-0001){ref-type="ref"} Poor glycaemic control has been causally associated with increased risk of diabetes‐related complications and mortality risk,[2](#dmrr3015-bib-0002){ref-type="ref"}, [3](#dmrr3015-bib-0003){ref-type="ref"} and glycaemic control is the main way to improve disease outcomes in clinical practice. Most studies examining the relationship between HbA~1c~ and outcomes have used HbA~1c~ measured at a single time point or derived summary measures that include average HbA~1c~ during follow‐up, change in HbA~1c~ over time, or HbA~1c~ variability.[4](#dmrr3015-bib-0004){ref-type="ref"}, [5](#dmrr3015-bib-0005){ref-type="ref"}, [6](#dmrr3015-bib-0006){ref-type="ref"}, [7](#dmrr3015-bib-0007){ref-type="ref"} However, these analytical approaches may not be able to completely capture the information available in serial HbA~1c~ measurements. Specifically, they fail to capture the trajectory of change over time. Existing data suggest that patients with diabetes in the population may have heterogeneous HbA~1c~ trajectories,[8](#dmrr3015-bib-0008){ref-type="ref"} and these trajectories may not be correlated to baseline or average HbA~1c~ levels; ie, patients with the same baseline or average HbA~1c~ may exhibit different patterns of change over time, or patients may exhibit the same pattern of change over time but have this change occur at different levels of average HbA~1c~. Previous studies have largely omitted these considerations in their analyses of the relationship between glycaemic control and diabetic outcomes.

In recent years, some studies have specifically examined if populations of patients with diabetes can be clustered to distinct groups based on the pattern of HbA~1c~ control over time. This has been made possible by the use of group‐based trajectory analysis, a relatively new statistical method that clusters individuals based on the trajectories of outcomes.[9](#dmrr3015-bib-0009){ref-type="ref"}, [10](#dmrr3015-bib-0010){ref-type="ref"} In addition to diabetes, this technique has been applied to various areas of clinical research including physical aggression, cortisol levels, internet usage, obesity, anxiety, depression,[11](#dmrr3015-bib-0011){ref-type="ref"} crime trends,[12](#dmrr3015-bib-0012){ref-type="ref"} and psychological disorders.[9](#dmrr3015-bib-0009){ref-type="ref"} Use of this analytical approach to identify distinct patterns may provide us with new insights into the diabetes disease process. Also, comparing characteristics between patients with different HbA~1c~ trajectories could help to identify modifiable factors underlying different HbA~1c~ patterns, which may be used for targeted intervention in diabetes management.

In this article, we aim to systematically review the existing literature on patterns of HbA~1c~ trajectories in patient populations with diabetes, to summarize (*a*) distinct HbA~1c~ patterns and prevalence of different patterns in the diabetes population, (*b*) factors associated with different HbA~1c~ patterns, and (*c*) outcomes associated with different patterns of HbA~1c~.

2. METHODS {#dmrr3015-sec-0006}
==========

2.1. Literature search {#dmrr3015-sec-0007}
----------------------

The protocol for this systematic review was registered on PROSPERO, the international prospective register of systematic reviews (unique identification number: CRD 42015019692) and is available in full on the National Institute for Health Research website.[13](#dmrr3015-bib-0013){ref-type="ref"} This systematic review was conducted in accordance with the Preferred Reporting Items for Systematic Reviews and Meta‐analyses statement.[14](#dmrr3015-bib-0014){ref-type="ref"}

PubMed and Web of Science databases were searched for potentially relevant articles from inception of database to September 2017. The search terms "HbA~1c~" or all the Medical Subject Headings terms of HbA~1c~ combined with "Trajector\* OR tracking OR longitudinal profile\* OR longitudinal data OR longitudinal level\* OR secular trend" were used with no restriction on publication date or languages. The last search was performed in September 2017. Hand searching of citations in included articles for references to other relevant studies was also conducted.

2.2. Study selection and eligibility criteria {#dmrr3015-sec-0008}
---------------------------------------------

Title and abstracts were evaluated to shortlist articles for this review and the eligibility of these articles were confirmed by a full‐text review using the following inclusion criteria: (*a*) longitudinal study of subjects with diabetes only, (*b*) use of serial measurements of HbA~1c~, and (*c*) analysis of the trend of HbA~1c~ using at least one of the group‐based trajectory modelling and clustering approaches,[10](#dmrr3015-bib-0010){ref-type="ref"} including latent class growth analysis, latent class growth mixture model, 2‐stage clustering method, *k*‐means cluster analysis, and hierarchical cluster analysis.

Studies that did not meet the inclusion criteria were excluded. Ineligible studies were excluded based on one or more of the following: irrelevant to the topic (eg, not evaluating glycaemic control); inappropriate study population (eg, nondiabetes population or a mixture of diabetes population and nondiabetes population); inappropriate study types (eg, cross‐sectional studies or case‐control studies); and inappropriate analysis methods (eg, not identifying clusters of patients with distinct HbA~1c~ trajectories).

Study selection was conducted independently by 2 authors. In the event of uncertainty, full text was examined, and discrepancies between authors were resolved by consultation between the 2 authors; if unable to reconcile, a third author was asked to review the title and abstract, or full text.

2.3. Data extraction and quality assessment {#dmrr3015-sec-0009}
-------------------------------------------

General information, study and subject characteristics, statistical methods to determine trajectories, and key findings were extracted for all the included articles. General information included authorship details, publication year, and country where the study was performed; study characteristics included study design, sample size, follow‐up duration, number and type of time points for HbA~1c~ data, and source of HbA~1c~ measures; subject characteristics included type of diabetes, age, diabetes duration, and baseline HbA~1c~ levels; statistical methods included the statistical model used for group‐based trajectory analysis, software used, approaches to determine the optimal number of subgroups, and number of clusters identified and attempted; key findings included HbA~1c~ trajectories identified and reported factors/outcomes associated with different patterns of trajectories.

Patterns of HbA~1c~ trajectories identified in each article were renamed and categorized based on baseline HbA~1c~ and trend of change. We used 5 categories to classify the baseline HbA~1c~ for both type 1 diabetes and type 2 diabetes: very low, low, moderate, moderate‐high, and high. However, the cut‐off values used to define these categories were different, considering the different target HbA~1c~ levels for type 1 diabetes and type 2 diabetes recommended in international guidelines.[15](#dmrr3015-bib-0015){ref-type="ref"} The HbA~1c~ cut‐off values were ≤7.0%, 7.1% to 7.5%, 7.6% to 9.0%, 9.1% to 11.0%, and \>11.0% for the 5 type 1 diabetes categories and ≤6.5%, 6.6% to 7.0%, 7.1% to 8.0%, 8.1% to 10.0%, and \>10.0% for type 2 diabetes. Trends of change were categorized into stable, deteriorating, improving, and other non‐linear trends. Stable trends were trajectories with a change of HbA~1c~ less than 1.0% during follow‐up as compared with baseline; deteriorating and improving trends were increasing or decreasing HbA~1c~ with a change of more than 1.0% as compared with baseline during follow‐up; non‐linear trends included patterns that had more than 1 trend during follow‐up, eg, increasing first and then decreasing. If baseline HbA~1c~ or trend of change was not given in numbers, estimates were extracted from the plot of HbA~1c~ trajectories.

Quality of the studies was assessed using the Newcastle‐Ottawa quality assessment scale[16](#dmrr3015-bib-0016){ref-type="ref"}, [17](#dmrr3015-bib-0017){ref-type="ref"} and Strengthening the Reporting of Observational studies in Epidemiology (STROBE) statements[18](#dmrr3015-bib-0018){ref-type="ref"} for cohort studies. Nine items of the Newcastle‐Ottawa quality assessment scale of cohort studies and 22 items of STROBE statements were evaluated for each article. Studies that fulfilled ≥8 items in the Newcastle‐Ottawa scale and ≥15 items in the STROBE statement were considered of good quality. Two studies with a randomized controlled trial design were also evaluated in the same manner as described earlier as such studies can be viewed as a prospective cohort design in terms of the HbA~1c~ trajectory analysis. Data extraction and quality assessment were conducted by 2 authors independently.

3. RESULTS {#dmrr3015-sec-0010}
==========

3.1. Study selection {#dmrr3015-sec-0011}
--------------------

The search identified 1379 nonduplicated articles. After the review of titles and abstracts, we excluded articles with irrelevant topics (n = 829), nondiabetic population (n = 185), cross‐sectional or case‐control study design (n = 44), and irrelevant analysis methods (n = 215). Of the 106 articles included for full‐text review, we further excluded 3 articles with nondiabetic population and 83 articles with irrelevant analysis methods. In total, 20 articles were included for data extraction. The Preferred Reporting Items for Systematic Reviews and Meta‐analyses flow diagram[19](#dmrr3015-bib-0019){ref-type="ref"} is displayed in Figure [1](#dmrr3015-fig-0001){ref-type="fig"}.

![Flowchart of study selection process](DMRR-34-na-g001){#dmrr3015-fig-0001}

3.2. Study characteristics {#dmrr3015-sec-0012}
--------------------------

The general information and study characteristics of the 20 included articles are summarized in Table [1](#dmrr3015-tbl-0001){ref-type="table"}. The studies were ordered by type of diabetes, year of publication, and first author\'s last name.

###### 

Summary of studies conducting group‐based HbA~1c~ trajectory analysis

  Study                                                               Country               Study design                             Sample size    Mean age (bl)          Mean diabetes duration (bl)   Length of follow‐up   No./type of time points[a](#dmrr3015-note-0003){ref-type="fn"}   HbA~1c~ data source/measurement method                                           HbA~1c~ trajectories identified
  ------------------------------------------------------------------- --------------------- ---------------------------------------- -------------- ---------------------- ----------------------------- --------------------- ---------------------------------------------------------------- -------------------------------------------------------------------------------- ----------------------------------------------
  **T1D**                                                                                                                                                                                                                                                                                                                                                                        
  Luyckx and Seiffge‐Krenke[55](#dmrr3015-bib-0055){ref-type="ref"}   Germany               Prospective cohort                       72             14 y                   4.8 y                         11 y                  8/structured                                                     Medical records/---                                                              Very low stable (13.9%, bl HbA~1c~ 6.3%)
  Moderate stable (70.8%, bl HbA~1c~ 7.6%)                                                                                                                                                                                                                                                                                                                                       
  Very low deteriorating (15.3%, bl HbA~1c~ 6.6%)                                                                                                                                                                                                                                                                                                                                
  Helgeson et al[58](#dmrr3015-bib-0058){ref-type="ref"}              United States         Prospective cohort                       132            12 y                   4.9 y                         5 y                   13/unstructured                                                  Medical records/HPLC (Tosoh)                                                     Moderate stable (63.7%)
  Moderate deteriorating (36.3%)                                                                                                                                                                                                                                                                                                                                                 
  King et al[23](#dmrr3015-bib-0023){ref-type="ref"}                  United States         Prospective cohort                       252            12 y                   4.7 y                         2 y                   8/unstructured                                                   Medical records/---                                                              Moderate stable (92%, average HbA~1c~ 8.18%)
  Moderate‐high deteriorating (8%, average HbA~1c~ 12.09%)                                                                                                                                                                                                                                                                                                                       
  Hilliard et al[56](#dmrr3015-bib-0056){ref-type="ref"}              United States         Prospective cohort                       150            16 y                   6.0 y                         1.5‐2 y               4/structured                                                     Medical records/DCA+ 2000 (Bayer)                                                Low stable (39.8%, bl HbA~1c~ 7.4%)
  Moderate‐high stable (39.7%, bl HbA~1c~ 9.2%)                                                                                                                                                                                                                                                                                                                                  
  High stable (20.5%, bl HbA~1c~ 11.2%)                                                                                                                                                                                                                                                                                                                                          
  Lawes et al[60](#dmrr3015-bib-0060){ref-type="ref"}                 Scotland              Retrospective cohort                     155            8 y (at recruitment)   Newly diagnosed               4.8 y                 ---/unstructured                                                 Medical records/DCA 2000 (Bayer)                                                 Low stable (21%)
  Moderate stable (33%)                                                                                                                                                                                                                                                                                                                                                          
  Moderate deteriorating (34%)                                                                                                                                                                                                                                                                                                                                                   
  Moderate‐high deteriorating (2%)                                                                                                                                                                                                                                                                                                                                               
  Phan et al[21](#dmrr3015-bib-0021){ref-type="ref"}                  United States         Retrospective cohort                     1449           11 y                   ---                           3 y                   9/unstructured                                                   Medical records/DCA Vantage (Siemens)                                            Moderate stable (58.1%, bl HbA~1c~ 8.0%)
  Moderate improving (25.5%, bl HbA~1c~ 8.8%)                                                                                                                                                                                                                                                                                                                                    
  Moderate deteriorating (16.4%, bl HbA~1c~ 8.3%)                                                                                                                                                                                                                                                                                                                                
  Rohan et al[20](#dmrr3015-bib-0020){ref-type="ref"}                 United States         Prospective cohort                       239            11 y                   4.4 y                         3 y                   7/structured                                                     Direct assessment/TOSOH‐G7                                                       Low stable (42.9%, bl HbA~1c~ 7.3%)
  Moderate deteriorating (44.6%, bl HbA~1c~ 8.6%)                                                                                                                                                                                                                                                                                                                                
  Moderate‐high deteriorating (12.1%, bl HbA~1c~ 10.0%)                                                                                                                                                                                                                                                                                                                          
  Marshall et al[30](#dmrr3015-bib-0030){ref-type="ref"}              Rwanda                Prospective cohort                       214            18 y                   3.4 y                         1‐2 y                 9/structured                                                     Direct assessment/DCA Vantage (Siemens)                                          Very low stable (8.0%, average HbA~1c~ 6.5%)
  Moderate deteriorating (8.4%, average HbA~1c~ 8.6%)                                                                                                                                                                                                                                                                                                                            
  Moderate‐high improving (26.9%, average HbA~1c~ 10.7%)                                                                                                                                                                                                                                                                                                                         
  High improving (31.8%, average HbA~1c~ 12.9%)                                                                                                                                                                                                                                                                                                                                  
  High stable (24.9%, average HbA~1c~ 13.5%)                                                                                                                                                                                                                                                                                                                                     
  Monaghan et al[22](#dmrr3015-bib-0022){ref-type="ref"}              United States         Retrospective cohort                     74             18 y                   9.0 y                         2 y                   5/structured                                                     Medical records/---                                                              Low stable (69%, bl HbA~1c~ 7.4%)
  Moderate‐high improving (31%, bl HbA~1c~ 10.5%)                                                                                                                                                                                                                                                                                                                                
  Viner et al[44](#dmrr3015-bib-0044){ref-type="ref"}                 United Kingdom        Prospective cohort                       384            13 y                   ---                           From age 9 to 17 y    6.7/unstructured                                                 Medical records/DCA 2000+ (Siemens)                                              Low stable (45.1%)
  Moderate deteriorating (39.6%)                                                                                                                                                                                                                                                                                                                                                 
  Moderate deteriorating fast (6.5%)                                                                                                                                                                                                                                                                                                                                             
  High stable (8.8%)                                                                                                                                                                                                                                                                                                                                                             
  Schwandt et al[45](#dmrr3015-bib-0045){ref-type="ref"}              Germany and Austria   Prospective cohort                       6443           9 y                    4.1 y                         From age 8 to 19 y    ---/unstructured                                                 Medical records/ National Glycohemoglobin Standardization Program standardized   Very low stable (26.9%, bl HbA~1c~ 6.6%)
  Low stable (40%, bl HbA~1c~ 7.4%)                                                                                                                                                                                                                                                                                                                                              
  Moderate stable (16. 6%, bl HbA~1c~ 8.4%)                                                                                                                                                                                                                                                                                                                                      
  Low deteriorating (13.0%, bl HbA~1c~ 7.4%)                                                                                                                                                                                                                                                                                                                                     
  Moderate deteriorating (5.4%, bl HbA~1c~ 8.5%)                                                                                                                                                                                                                                                                                                                                 
  **T2D**                                                                                                                                                                                                                                                                                                                                                                        
  Bayliss et al[28](#dmrr3015-bib-0028){ref-type="ref"}               United States         3 subcohorts from a prospective cohort   582 (cancer)   66 y                   ---                           4.7 y                 9/unstructured                                                   Medical records/---                                                              Very low stable (37.7%)
  Moderate stable (41.0%)                                                                                                                                                                                                                                                                                                                                                        
  Moderate‐high deteriorating (7.4%)                                                                                                                                                                                                                                                                                                                                             
  High improving (10.6%)                                                                                                                                                                                                                                                                                                                                                         
  High stable (3.2%)                                                                                                                                                                                                                                                                                                                                                             
  2959 (depression)                                                   62 y                  ---                                      5.0 y          8/unstructured         Low stable (49.7%)                                                                                                                                                                                    
  Moderate‐high stable (32.5%)                                                                                                                                                                                                                                                                                                                                                   
  Moderate‐high deteriorating (8.4%)                                                                                                                                                                                                                                                                                                                                             
  High improving (6.2%)                                                                                                                                                                                                                                                                                                                                                          
  High stable (3.2%)                                                                                                                                                                                                                                                                                                                                                             
  2322 (pulmonary disease)                                            63 y                  ---                                      5.0 y          9/unstructured         Very low stable (48.2%)                                                                                                                                                                               
  Moderate stable (31.8%);                                                                                                                                                                                                                                                                                                                                                       
  Moderate‐high stable (12.6%)                                                                                                                                                                                                                                                                                                                                                   
  High U shape (1.4%)                                                                                                                                                                                                                                                                                                                                                            
  High N shape (5.9%)                                                                                                                                                                                                                                                                                                                                                            
  Wang and Hazuda[57](#dmrr3015-bib-0057){ref-type="ref"}             United States         Prospective cohort                       119            76 y                   12.5 y                        3.0 y                 7/structured                                                     Direct assessment/---                                                            Very low stable (44.7%)
  Moderate stable (55.3%)                                                                                                                                                                                                                                                                                                                                                        
  Chang et al[24](#dmrr3015-bib-0024){ref-type="ref"}                 Taiwan                RCT                                      1091           56 y                   10.0 y                        4.5 y                 9/structured                                                     Direct assessment/Variant II (Bio‐Rad Laboratories)                              Low stable (47.2%)
  Moderate‐high stable (38.3%)                                                                                                                                                                                                                                                                                                                                                   
  High stable (14.5%)                                                                                                                                                                                                                                                                                                                                                            
  Ravona‐Springer et al[62](#dmrr3015-bib-0062){ref-type="ref"}       Israel                Prospective cohort                       835            73 y                   ---                           8.7 y                 18/unstructured                                                  Medical records/---                                                              Very low stable (27.1%, bl HbA~1c~ 6.0%)
  Low stable (43.6%, bl HbA~1c~ 6.8%)                                                                                                                                                                                                                                                                                                                                            
  Moderate stable (14.7%, bl HbA~1c~ 7.3%)                                                                                                                                                                                                                                                                                                                                       
  Moderate deteriorating (5.5%, bl HbA~1c~ 7.8%)                                                                                                                                                                                                                                                                                                                                 
  Moderate‐high improving (7.1%, bl HbA~1c~ 9.2%)                                                                                                                                                                                                                                                                                                                                
  High improving (1.8%, bl HbA~1c~ 10.7%)                                                                                                                                                                                                                                                                                                                                        
  Migliore et al[59](#dmrr3015-bib-0059){ref-type="ref"}              United States         RCT                                      109            ---                    ---                           2 y                   6/structured                                                     Direct assessment/Glyc‐affin Ghd column method                                   Moderate non‐linear (74.3%)
  Moderate‐high non‐linear (22.0%)                                                                                                                                                                                                                                                                                                                                               
  Walraven et al[26](#dmrr3015-bib-0026){ref-type="ref"}              The Netherlands       Prospective cohort                       5432           61 y                   1.0 y                         5.7 y                 9/structured                                                     Direct assessment/HA‐8160 analyser, Menarini                                     Low stable (83.1%, bl HbA~1c~ 6.9%)
  Moderate deteriorating (3.4%, bl HbA~1c~ 7.9%)                                                                                                                                                                                                                                                                                                                                 
  Moderate‐high improving (5.2%, bl HbA~1c~ 9.1%)                                                                                                                                                                                                                                                                                                                                
  High improving (L shape) (8.2%, bl HbA~1c~ 11.9%)                                                                                                                                                                                                                                                                                                                              
  Mast et al[61](#dmrr3015-bib-0061){ref-type="ref"}                  The Netherlands       Prospective cohort                       1203           65 y                   8.3 y                         5.6 y                 12/structured                                                    Direct assessment/HA‐8160 analyser, Menarini                                     Moderate stable (88.7%, bl HbA~1c~ 7.4%)
  Moderate‐high N shape (3.0%, bl HbA~1c~ 8.1%)                                                                                                                                                                                                                                                                                                                                  
  Moderate‐high improving slow (3.9%, bl HbA~1c~ 10.0%)                                                                                                                                                                                                                                                                                                                          
  High improving fast (4.4%, bl HbA~1c~ 10.9%)                                                                                                                                                                                                                                                                                                                                   
  Laiteerapong et al[25](#dmrr3015-bib-0025){ref-type="ref"}          United States         Prospective cohort                       28 016         ---                    Newly diagnosed               13.6 y                10/structured                                                    Medical records/HPLC                                                             Moderate stable (82.5%, bl HbA~1c~ 7.2%)
  Moderate‐high deteriorating (5.1%, bl HbA~1c~ 8.3%)                                                                                                                                                                                                                                                                                                                            
  Moderate‐high peaking late (N shape) (4.1%, bl HbA~1c~ 8.5%)                                                                                                                                                                                                                                                                                                                   
  Moderate‐high peaking early (N shape) (3.3%, bl HbA~1c~ 9.3%)                                                                                                                                                                                                                                                                                                                  
  High improving (4.9%, bl HbA~1c~ 11.9%)                                                                                                                                                                                                                                                                                                                                        
  Luo et al[27](#dmrr3015-bib-0027){ref-type="ref"}                   Singapore             Ambispective cohort                      6079           59 y                   4.5 y                         4.1 y                 ---/unstructured                                                 Medical records/---                                                              Moderate stable (72.2%, bl HbA~1c~ 7.2%)
  Moderate‐high stable (22.0%, bl HbA~1c~ 8.9%)                                                                                                                                                                                                                                                                                                                                  
  High deteriorating (2.9%, bl HbA~1c~ 10.4%)                                                                                                                                                                                                                                                                                                                                    
  High improving (2.8%, bl HbA~1c~ 12.1%)                                                                                                                                                                                                                                                                                                                                        

Abbreviations: ---, not mentioned; bl, baseline; HPLC, high‐performance liquid chromatography; RCT, randomized control trial.

Patterns of HbA~1c~ trajectories were renamed and categorized based on baseline HbA~1c~ and trend of change. Baseline HbA~1c~ were categorized based on the following cut‐off points: ≤7.0% (very low), 7.1% to 7.5% (low), 7.6% to 9.0% (moderate), 9.1% to 11.0% (moderate‐high), and \>11.0% (high) for type 1 diabetes; ≤ 6.5% (very low), 6.6% to 7.0% (low), 7.1% to 8.0% (moderate), 8.1% to 10.0% (moderate‐high), and \>10.0% (high) for type 2 diabetes patients.

Structured time points: studies that used predesigned or reshaped measurement intervals in the trajectory model; unstructured time points: studies that used original measurement intervals as in clinical practice. For studies with unstructured time points, the number of time points refers to the average number of HbA~1c~ measurements for each participant.

All 20 included studies were published in international journals within the recent decade (from 2009 to 2017). The majority of the studies were conducted in the United States (n = 10), followed by Europe (n = 6) and Asia (n = 3), and one study was conducted in Africa. Fourteen of these studies were prospective cohort studies, 3 were retrospective cohort studies, 1 was an ambispective cohort study, and 2 were randomized controlled trials. Eleven of the studies were conducted among type 1 diabetes patients (mean age at baseline 8‐18 y), and 9 studies were conducted among type 2 diabetes patients (mean age at baseline 56‐76 y). The sample size for the 20 studies ranged from 72 to 28 016 subjects, and follow‐up duration ranged from 2 to 13.6 years. Thirteen studies acquired HbA~1c~ values from medical records, while the rest obtained HbA~1c~ values by direct measurement. Half of the studies used the National Glycohemoglobin Standardization Program--certified method for the measurement of HbA~1c~ (n = 10). One study mathematically standardized their results to the reference range of the Diabetes Control and Complications Trial (n = 1), while the rest did not report their HbA~1c~ measurement methods or standardization processes (n = 9). The number of HbA~1c~ points for each subject ranged from 4 to 18. Twelve of these studies used structured time points in the HbA~1c~ trajectory analysis, and the time points in the remaining 8 studies were unstructured.

3.3. Statistical methods used in group‐based HbA~1c~ trajectory analysis {#dmrr3015-sec-0013}
------------------------------------------------------------------------

The statistical models used for analysing HbA~1c~ trajectories included latent class growth analysis (n = 14), latent class growth mixture model (n = 3), 2‐stage clustering method (n = 1), *k*‐means cluster analysis (n = 1), and hierarchical cluster analysis (n = 1) (Table [2](#dmrr3015-tbl-0002){ref-type="table"}). The maximum number of clusters evaluated during the model selection was less or equal to 7 in all the studies, and the number of clusters identified in the final model ranged from 2 to 6 (final model: 2 clusters, n = 5; 3 clusters, n = 5; 4 clusters, n = 5; 5 clusters, n = 4; 6 clusters, n = 1). Bayesian information criterion was the most commonly used tool for determining the optimal number of subgroups (n = 15), and it was often used in combination with other statistics, which included Akaike information criterion, entropy, average posterior probabilities, bootstrapped likelihood ratio test, Lo‐Mendell‐Rubin likelihood ratio test, sufficient subject in each group, clinical plausibility, and other model diagnostics.

###### 

Statistical methods used by studies conducting group‐based HbA~1c~ trajectory analysis

  Study                                                               Statistical method              Software        Dependent variable                            Independent variable                           Approach to determine number of clusters   No. of clusters attempted   No. of clusters in the final model                                                                                                                    
  ------------------------------------------------------------------- ------------------------------- --------------- --------------------------------------------- ---------------------------------------------- ------------------------------------------ --------------------------- ------------------------------------ --------- ---------------------------------------- --------- --------------------------------------- ----------- ---
  **T1D**                                                                                                                                                                                                                                                                                                                                                                                                                                       
  Luyckx and Seiffge‐Krenke[55](#dmrr3015-bib-0055){ref-type="ref"}   LCGA                            Mplus           HbA~1c~                                       Time from recruitment                          ✓                                          ---                         ✓ (*E* = 0.99)                       ---       Bootstrapped likelihood ratio test       ✓         ---                                     2‐4         3
  Helgeson et al[58](#dmrr3015-bib-0058){ref-type="ref"}              LCGA                            SAS Proc TRAJ   HbA~1c~                                       Time from recruitment                          ✓                                          ---                         ---                                  ---       ---                                      ---       ---                                     2‐4         2
  King et al[23](#dmrr3015-bib-0023){ref-type="ref"}                  LCGA                            Mplus           HbA~1c~                                       Age                                            ✓                                          ---                         ✓ (*E* = 0.92)                       ✓         Lo‐Mendell‐Rubin likelihood ratio test   ---       ---                                     1‐3         2
  Hilliard et al[56](#dmrr3015-bib-0056){ref-type="ref"}              LCGA                            Mplus           HbA~1c~, BGM frequency                        Time from recruitment                          ✓                                          ---                         ---                                  ---       ---                                      ✓ (10%)   Nagin\'s diagnostics                    2‐4         3
  Lawes et al[60](#dmrr3015-bib-0060){ref-type="ref"}                 Two‐stage clustering method     SPSS            HbA~1c~                                       Time from diagnosis of diabetes                ✓                                          ---                         ---                                  ---       ---                                      ---       Distant change                          Maximum 6   4
  Phan et al[21](#dmrr3015-bib-0021){ref-type="ref"}                  Hierarchical cluster analysis   SAS and SPSS    HbA~1c~                                       Time from study baseline                       ---                                        ---                         ---                                  ---       ---                                      ---       ---                                     ---         3
  Rohan et al[20](#dmrr3015-bib-0020){ref-type="ref"}                 LCGA                            SAS Proc TRAJ   HbA~1c~                                       Time from recruitment                          ✓                                          ---                         ---                                  ---       ---                                      ✓ (10%)   Nagin\'s diagnostics                    2‐6         3
  Marshall et al[30](#dmrr3015-bib-0030){ref-type="ref"}              LCGA                            SAS Proc TRAJ   HbA~1c~                                       Time from recruitment                          ✓[a](#dmrr3015-note-0005){ref-type="fn"}   ---                         ---                                  ---       ---                                      ---       ---                                     ---         5
  Monaghan et al[22](#dmrr3015-bib-0022){ref-type="ref"}              LCGA                            SAS Proc TRAJ   HbA~1c~                                       Time from college enrolment                    ✓                                          ---                         ---                                  ---       ---                                      ✓ (\>5)   ---                                     ---         2
  Viner et al[44](#dmrr3015-bib-0044){ref-type="ref"}                 LCGMM                           Mplus           HbA~1c~                                       Age                                            ✓[b](#dmrr3015-note-0006){ref-type="fn"}   ✓                           ✓                                    ---       Lo‐Mendell‐Rubin likelihood ratio test   ---       Clinical plausibility                   1‐4         4
  Schwandt et al[45](#dmrr3015-bib-0045){ref-type="ref"}              LCGA                            SAS Proc TRAJ   HbA~1c~                                       Age                                            ✓                                          ---                         ---                                  ---       ---                                      ✓ (5%)    Clinical plausibility                   1‐6         5
  **T2D**                                                                                                                                                                                                                                                                                                                                                                                                                                       
  Bayliss et al[28](#dmrr3015-bib-0028){ref-type="ref"}               LCGA                            ---             HbA~1c~                                       Time from diagnosis of incident co‐morbidity   ---                                        ---                         ---                                  ---       ---                                      ---       ---                                     ---         5
  Wang and Hazuda[57](#dmrr3015-bib-0057){ref-type="ref"}             LCGMM                           ---             HbA~1c~                                       Time from recruitment                          ✓                                          ✓                           ---                                  ---       ---                                      ---       Residual diagnostics                    ---         2
  Chang et al[24](#dmrr3015-bib-0024){ref-type="ref"}                 LCGA                            SAS Proc TRAJ   HbA~1c~                                       Time from recruitment                          ✓                                          ---                         ---                                  ---       ---                                      ---       ---                                     ---         3
  Ravona‐Springer et al[62](#dmrr3015-bib-0062){ref-type="ref"}       LCGA                            SAS Proc TRAJ   HbA~1c~                                       Time from entry to diabetes registry           ---                                        ---                         ---                                  ---       ---                                      ---       Nagin\'s diagnostics                    ---         6
  Migliore et al[59](#dmrr3015-bib-0059){ref-type="ref"}              *k*‐means cluster analysis      SPSS            HbA~1c~, blood pressure, BMI, triglycerides   Time from recruitment                          ---                                        ---                         ---                                  ---       ---                                      ---       Hierarchical clustering; intervention   ---         2
  Walraven et al[26](#dmrr3015-bib-0026){ref-type="ref"}              LCGA                            Mplus           HbA~1c~                                       Time from recruitment                          ✓                                          ---                         ---                                  ✓ (0.8)   ---                                      ---       Clinical plausibility                   1‐5         4
  Mast et al[61](#dmrr3015-bib-0061){ref-type="ref"}                  LCGA                            Mplus           HbA~1c~                                       Time from insulin initiation                   ✓                                          ---                         ---                                  ✓ (0.8)   ---                                      ✓ (1%)    Clinical plausibility                   ---         4
  Laiteerapong et al[25](#dmrr3015-bib-0025){ref-type="ref"}          LCGMM                           Mplus           HbA~1c~                                       Time from diagnosis of diabetes                ---                                        ---                         ---                                  ---       Lo‐Mendell‐Rubin likelihood ratio test   ✓ (1%)    ---                                     ---         5
  Luo et al[27](#dmrr3015-bib-0027){ref-type="ref"}                   LCGA                            R               HbA~1c~                                       Time from recruitment                          ✓                                                                                                           ✓ (0.8)   ---                                      ---       ---                                     2‐7         4

Abbreviations: ---, not mentioned; AIC, Akaike information criterion; BIC, Bayesian information criterion; BMI, body mass index; LCGA, latent class growth analysis; LCGMM, latent class growth mixture model; T1D, type 1 diabetes; T2D, type 2 diabetes.

BIC log Bayes factor approximation was used: 2 log~e~(B10) ≅ 2(ΔBIC).

Sample adjusted BIC.

3.4. Summary of HbA~1c~ trajectories identified {#dmrr3015-sec-0014}
-----------------------------------------------

As summarized in Table [1](#dmrr3015-tbl-0001){ref-type="table"}, different HbA~1c~ patterns were identified in each study. Although these patterns were named differently in each article, we have renamed and categorized these patterns based on baseline HbA~1c~ (very low, low, moderate, moderate‐high, and very high) and trend of change (stable, deteriorating, improving, and other non‐linear trends) as described in the Section [2](#dmrr3015-sec-0006){ref-type="sec"} above. The very low stable and low stable trajectories indicated optimal glycaemic control status, with stable control below the target HbA~1c~ level maintained over the follow‐up period. The other patterns indicated poorer glycaemic control status to different extents.

Among studies on type 1 diabetes (n = 11), most studies (n = 6) identified a group of patients that maintained stable HbA~1c~ levels at a low baseline of 7.1% to 7.5%, containing 21% to 69% of the sample. Another stable trajectory pattern with moderate baseline levels of HbA~1c~ (7.6%‐9.0%) was also frequently observed (n = 6), with the proportion ranging from 17% to 92%. These 2 patterns were usually the largest subgroups in the study population. Three studies also identified a stable pattern at a very low baseline level (6.0%‐7.0%), and another 3 studies identified a cluster with continuously poor control with HbA~1c~ maintained at a moderate high (9.1%‐11.0%) or very high baseline level (higher than 11.0%), and each pattern usually contained less than one‐third of the sample. Groups with deteriorating HbA~1c~, from very low (n = 1), low (n = 1), moderate (n = 7), and moderate‐high (n = 3) baseline HbA~1c~, were also identified, with the proportion ranging from 2% to 45%. The group deteriorating from moderate baseline level was most commonly observed in studies. Three studies also identified groups with improving HbA~1c~ over time, with the proportion ranging from 26% to 32%.

Among studies on type 2 diabetes (n = 9), the most commonly identified pattern was the moderate stable group (n = 7) with a HbA~1c~ level slightly above the 7.0% target level. This group was usually the largest cluster, containing 15% to 89% of the sample. Two groups with a HbA~1c~ level below the 7.0% target level and below a more stringent 6.5% level were also identified, ie, low stable (n = 4) and very low stable group (n = 4). The low stable group contained 44% to 83% of the sample, and the very low stable group contained 27% to 48% of the sample. Groups with stable HbA~1c~ level at a moderately high level (7.1% to 8.0%) were found in 4 studies, with group percentages of 13% to 38%. Two studies identified a small proportion of patients (3% and 15%, respectively) that maintained high HbA~1c~ levels over time. Groups with deteriorating glycaemic control starting from moderate (n = 2) or moderate‐high (n = 4) HbA~1c~ level were identified in 5 studies, which consisted of 3% to 8% of the sample. Groups with improving control starting from moderate‐high (n = 3) or high (n = 6) baseline HbA~1c~ level were identified in 6 studies, with group percentage ranging from 2% to 11%. Other non‐linear patterns, including U shaped (n = 1), N shaped (n = 3), and L shaped (n = 1), were also observed in a small number of studies.

3.5. Factors and outcomes associated with HbA~1c~ trajectories {#dmrr3015-sec-0015}
--------------------------------------------------------------

Table [3](#dmrr3015-tbl-0003){ref-type="table"} summarizes the reported factors associated with HbA~1c~ trajectories in studies on patients with type 1 diabetes. Among demographic factors, older age, female gender, and ethnic minority status were associated with poor HbA~1c~ trajectories. Disease‐related factors associated with poor HbA~1c~ trajectories included longer diabetes duration, less physical activity, fewer glucose monitoring frequencies, fewer or missed clinical appointments, and insulin treatment via injection versus insulin pump. Phan et al have shown that the association of age, ethnicity, and fewer or missed clinical appointments with deteriorating HbA~1c~ trajectory was significant after adjustment for baseline HbA~1c~.[21](#dmrr3015-bib-0021){ref-type="ref"} Since the study population comprised mainly children and adolescents, family environment variables including poor family climate or family conflict and parental involvement in care were also found to be associated with poor glycaemic control. Psychosocial variables, including negative emotions and poorer self‐control, and onset of puberty were also associated with poorer control. In addition, Monaghan et al also found that 31% of adolescents showed deteriorating HbA~1c~ upon college entry,[22](#dmrr3015-bib-0022){ref-type="ref"} and King et al reported that subjects with poorer HbA~1c~ trajectories had more frequent diabetes‐related emergency room visits and diabetes‐related hospitalizations.[23](#dmrr3015-bib-0023){ref-type="ref"}

###### 

Factors associated with poorer glycaemic control trajectories in patients with type 1 diabetes

  Studies                                                                                                         Demographics   Disease related   Family environment   Psychosocial   Others                                                                
  --------------------------------------------------------------------------------------------------------------- -------------- ----------------- -------------------- -------------- -------- ----- ------------------------------------ ----- ----- ----- ------------------------------------------------------------------------------------------------------------------------------
  Luyckx and Seiffge‐Krenke[55](#dmrr3015-bib-0055){ref-type="ref"} ^,^ [a](#dmrr3015-note-0008){ref-type="fn"}   ---            ✓                 ---                  ns             ---      ---   ---                                  ✓     ✓     ✓     ns: Family composition, socio‐economic status, and BMI score
  Helgeson et al[58](#dmrr3015-bib-0058){ref-type="ref"} ^,^ [b](#dmrr3015-note-0009){ref-type="fn"}              ns             ns                ---                  ---            ✓        ✓     ns after adjustment for bl HbA~1c~   ---   ✓     ✓     ✓: Peer conflict, lower social status, higher pubertal status, higher BMI
  King et al[23](#dmrr3015-bib-0023){ref-type="ref"} ^,^ [c](#dmrr3015-note-0010){ref-type="fn"}                  ---            ---               ---                  ---            ---      ---   ---                                  ✓     ---   ✓     ✓: Diabetes‐related emergency room visit and hospitalizations
  Hilliard et al[56](#dmrr3015-bib-0056){ref-type="ref"} ^,^ [c](#dmrr3015-note-0010){ref-type="fn"}              ✓              ---               ✓                    ✓              ---      ---   ✓                                    ✓     ✓     ✓     ✓: Unmarried caregiver status
  Lawes et al[60](#dmrr3015-bib-0060){ref-type="ref"} ^,^ [a](#dmrr3015-note-0008){ref-type="fn"}                 ✓              ---               ---                  ---            ---      ✓     ns at 2 y after diagnosis            ---   ---   ---   ✓: More frequent nonclinic health care contacts; higher rates of adverse psychosocial variables
  Phan et al[21](#dmrr3015-bib-0021){ref-type="ref"} ^,^ [d](#dmrr3015-note-0011){ref-type="fn"}                  ✓              ---               ✓                    ---            ---      ✓     ---                                  ---   ---   ---   ✓: Medicaid vs commercial insurance
  Rohan et al[20](#dmrr3015-bib-0020){ref-type="ref"} ^,^ [e](#dmrr3015-note-0012){ref-type="fn"}                 ---            ✓                 ns                   ns             ✓        ---   ns                                   ✓     ---   ns    ---
  Marshall et al[30](#dmrr3015-bib-0030){ref-type="ref"} ^,^ [a](#dmrr3015-note-0008){ref-type="fn"}              ns             ---               ---                  ns             ✓        ---   ---                                  ---   ---   ---   ns: Rates did not differ for bl microalbuminuria, neuropathy, and nephropathy; test not conducted owing to small sample size
  Monaghan et al[22](#dmrr3015-bib-0022){ref-type="ref"} ^,^ [a](#dmrr3015-note-0008){ref-type="fn"}              ---            ---               ✓                    ---            ---      ---   ✓                                    ---   ---   ---   ✓: College entry
  Viner et al[44](#dmrr3015-bib-0044){ref-type="ref"} ^,^ [e](#dmrr3015-note-0012){ref-type="fn"}                 ---            ns                ns                   ns             ---      ns    ✓                                    ---   ---   ---   ---
  Schwandt et al[45](#dmrr3015-bib-0045){ref-type="ref"} ^,^ [e](#dmrr3015-note-0012){ref-type="fn"}              ns             ✓                 ---                  ---            ✓        ---   ns                                   ---   ---   ---   ✓: Increased daily insulin dose, less physical activity; lower BMI SD score, height SD score

Abbreviations: ✓, associated; ---, not mentioned; bl, baseline; BMI, body mass index; ns, not significant; SD, standard deviation.

Unadjusted.

Adjusted for social status, pubertal status, BMI, and household structure. Results for other variables were unadjusted.

Adjusted for variables of the same categories (or with shared variance or in the same block).

Adjusted for baseline HbA~1c~ and all variables in the model.

Adjusted for all variables in the model.

Table [4](#dmrr3015-tbl-0004){ref-type="table"} presents the factors and outcomes associated with poorer HbA~1c~ trajectories in patients with type 2 diabetes. Younger age, ethnic minority status, and lower educational level were reported demographic factors associated with poorer HbA~1c~ trajectories. Disease‐related factors reported included longer diabetes duration, higher baseline HbA~1c~ levels, poorer lipid profiles, insulin treatment, and complications like deteriorating kidney function (higher albumin‐to‐creatinine ratio, microalbuminuria), retinopathy, neuropathy, and peripheral arterial disease. Multiple studies also reported the association between higher estimated glomerular filtration rate and poorer glycaemic control trajectories. Inconsistent findings were reported for body mass index (BMI), and Chang et al found that patients with poorer glycaemic control had lower BMI,[24](#dmrr3015-bib-0024){ref-type="ref"} while the other 3 studies found higher BMI was associated with poorer glycaemic control.[25](#dmrr3015-bib-0025){ref-type="ref"}, [26](#dmrr3015-bib-0026){ref-type="ref"}, [27](#dmrr3015-bib-0027){ref-type="ref"} In addition, Bayliss et al reported that the HbA~1c~ trajectories did not change significantly before and after the incident co‐morbidity of cancer, depression, and pulmonary disease.[28](#dmrr3015-bib-0028){ref-type="ref"} In terms of outcomes, poor HbA~1c~ trajectories were associated with risk of microvascular and macrovascular events and mortality, poorer cognitive function, and poorer lower‐extremity function. Laiteerapong et al reported higher incidence of microvascular complications in all the nonstable trajectories and increased all‐cause mortality risk for groups with high improving trajectory as compared with the low stable group, after adjustment for mean HbA~1c~.[25](#dmrr3015-bib-0025){ref-type="ref"} Luo et al reported increased risk of stroke, end‐stage renal disease, and all‐cause mortality in moderate‐increase and high‐decrease trajectories as compared with the low stable group, after adjustment for baseline HbA~1c~.[27](#dmrr3015-bib-0027){ref-type="ref"}

###### 

Factors and outcomes associated with poorer glycaemic control trajectories in patients with type 2 diabetes

  Studies                                                                                                                                              Factors                                    Outcomes                                                                                                                                                                                                                                                                                                                                                                     
  ---------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------ ---------- ----- ----- ------------------------------------------ -------- -------- ------------- --------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------------------------------------------------------------- ----- -------------------------------------------------------------------
  Bayliss et al[28](#dmrr3015-bib-0028){ref-type="ref"}                                                                                                ---                                        ---        ---   ---   ---                                        ---      ---      ---           ns: Incident co‐morbidity                                                                                 ---                                                                                                                                                        ---   ---
  Wang and Hazuda[57](#dmrr3015-bib-0057){ref-type="ref"} ^,^ [a](#dmrr3015-note-0014){ref-type="fn"} ^,^ [b](#dmrr3015-note-0015){ref-type="fn"}      ✓                                          ---        ✓     ✓     ---                                        ---      ---      ---           ✓: Higher peripheral arterial disease prevalence                                                          ---                                                                                                                                                        ---   ✓: Poorer lower extremity function
  Chang et al[24](#dmrr3015-bib-0024){ref-type="ref"} ^,^ [b](#dmrr3015-note-0015){ref-type="fn"} ^,^ [c](#dmrr3015-note-0016){ref-type="fn"}          ✓                                          ---        ✓     ✓     ---                                        ✓ (bl)   ✓ (bl)   Lower (bl)    ✓: Less physical activity; higher ACR; higher neuropathy; higher family history of diabetes at bl         ✓: Higher incidence of retinopathy, nephropathy, stroke, hypoglycaemia, and ketoacidosis                                                                   ---   ✓: Higher use of oral anti‐hyperglycaemic medications and insulin
  Ravona‐Springer et al[62](#dmrr3015-bib-0062){ref-type="ref"} ^,b,d^                                                                                 ✓                                          ---        ns    ✓     ✓                                          ✓        ns       ---           ✓: Insulin treatment                                                                                      ---                                                                                                                                                        ---   ✓: Poorer cognitive function
  Migliore et al[59](#dmrr3015-bib-0059){ref-type="ref"} ^,b^                                                                                          ---                                        ---        ---   ---   ---                                        ---      ---      ---           ✓: Self‐management and coping skills training intervention                                                ---                                                                                                                                                        ---   ---
  Walraven et al[26](#dmrr3015-bib-0026){ref-type="ref"} ^,^ [d](#dmrr3015-note-0018){ref-type="fn"}                                                   ✓                                          ---        ---   ✓     ✓                                          ✓ (bl)   ---      Higher (bl)   ✓: Higher urinary ACR, microalbuminuria, and retinopathy; higher insulin use (bl)                         ✓: Higher prevalence of retinopathy, microalbuminuria                                                                                                      ---   ---
  Mast et al[61](#dmrr3015-bib-0061){ref-type="ref"} ^,^ [b](#dmrr3015-note-0015){ref-type="fn"}                                                       ✓[d](#dmrr3015-note-0018){ref-type="fn"}   ---        ---   ns    ✓[d](#dmrr3015-note-0018){ref-type="fn"}   ✓        ✓        ns            ✓: Higher SU use; ns: retinopathy, ns: microalbuminuria                                                   ---                                                                                                                                                        ✓     ---
  Laiteerapong et al[25](#dmrr3015-bib-0025){ref-type="ref"} ^,^ [b](#dmrr3015-note-0015){ref-type="fn"} ^,^ [e](#dmrr3015-note-0019){ref-type="fn"}   ✓                                          ✓          ---   ---   ✓                                          ✓        ✓        Higher        ✓: Less macrovascular diseases; more microvascular disease; smoking; higher blood pressure                ✓: Higher incidence of retinopathy, end‐stage renal disease, lower‐extremity amputation, and macrovascular events[f](#dmrr3015-note-0020){ref-type="fn"}   ✓     ---
  Luo et al[27](#dmrr3015-bib-0027){ref-type="ref"} ^,b,h^                                                                                             ✓                                          ✓          ---   ✓     ✓                                          ✓        ✓        Higher        ✓: Insulin treatment; bl co‐morbidities; managed in hospital outpatient clinics vs primary care clinics   ✓: Higher incidence of end‐stage renal disease, acute myocardial infarction, and stroke                                                                    ✓     ---

Abbreviations: ✓, associated; ---, not mentioned; ACR, albumin‐to‐creatinine ratio; bl, baseline; BMI, body mass index; eGFR, estimated glomerular filtration rate; ns, not significant.

Outcomes were analysed by path analysis with adjustment for age, education, ethnicity, BMI, angina, stroke, and pulmonary function.

Factors reported from comparisons without adjustment.

Outcomes were analysed by proportional hazards model with adjustment for age and BMI.

Outcomes were analysed by analysis of covariance with adjustment of sociodemographic, cardiovascular, diabetes‐related covariates, and geriatric depression scale score.

Factors reported from comparisons with adjustment.

Outcomes were analysed by Cox proportional hazards models with adjustment for age, gender, ethnicity, BMI, blood pressure, cholesterol, smoking, haemoglobin, eGFR, history of microvascular and macrovascular complications, co‐morbidity, and mean HbA~1c~.

The association of macrovascular events was insignificant after adjustment for mean HbA~1c~.

Outcomes were analysed by Cox proportional hazards models with adjustment for age, gender, ethnicity, BMI, blood pressure, cholesterol, eGFR, smoking, diabetes duration, insulin treatment, place receiving medical care, and HbA~1c~ at baseline.

4. DISCUSSION {#dmrr3015-sec-0016}
=============

In this study, 20 articles reporting long‐term HbA~1c~ trajectories were included. All but 2 were cohort studies with varying follow‐up durations. These studies identified 2 to 6 HbA~1c~ trajectory subgroups and also reported several factors and outcomes associated with trajectory groups.

The review showed that there was heterogeneity in HbA~1c~ trajectories within and between study populations. In type 1 diabetes, we found that studies commonly reported patients with 2 major trends of glycaemic control, one with stable control and one with unstable control. The stable group was usually considered the better control group with HbA~1c~ at an acceptable level (close to the 7.5% target), while the unstable group had either a deteriorating or improving trend. Although more than half of patients were grouped in the stable group in most of the studies, it is also worth noting that the proportions of patients with unstable trends were much higher in studies on type 1 diabetes (2%‐40%) compared with studies on type 2 diabetes (2%‐11%). These higher proportions may reflect the greater challenges in achieving glycaemic control in type 1 diabetes compared with type 2 diabetes.[29](#dmrr3015-bib-0029){ref-type="ref"}

In type 2 diabetes, most studies reported a group, usually the largest one, with relatively low and stable HbA~1c~ over time. However, the actual HbA~1c~ levels of the low stable group and the percentage of patients in this group varied substantially between different studies. There was greater heterogeneity among studies in relation to groups with less than optimal control over time. Many studies reported another stable group of patients albeit with higher levels of HbA~1c~, while some also found patients with extremely high but stable HbA~1c~ levels. In contrast, some studies observed groups with unstable levels of HbA~1c~, including patterns with improving control, deteriorating control, and other non‐linear trends. These differences might be due to the country where the study was conducted, patient characteristics, follow‐up duration, and the use of different statistical models. We observed that studies conducted in countries with well‐developed health care systems, ie, the United States and the Netherlands, generally had a larger proportion of patients in the trajectory with low and stable HbA~1c~ levels.[22](#dmrr3015-bib-0022){ref-type="ref"}, [26](#dmrr3015-bib-0026){ref-type="ref"}, [30](#dmrr3015-bib-0030){ref-type="ref"} Patient characteristics, including diabetes duration, place receiving diabetes management, and length of follow‐up, may have also influenced the patterns of trajectories identified and proportions of patients in each cluster. For example, more patterns were likely to emerge with longer duration of follow‐up. Identifying patterns of trajectories could help to map the glycaemic control in the population, which could be used for comparing across health care settings and populations. Knowing the distribution of HbA~1c~ patterns in the population could also be used contextually to help allocate medical resources in the health system efficiently and establish tailored policies and programmes to improve the glycaemic control in the given population. In addition, these patterns can also be useful in clinical settings, if membership of specific groups can be predicted early, to provide targeted intensification of therapies and additional diabetes management support to patients likely to have poorer glycaemic control trajectories. Such personalization of care can lead to substantial improvements in outcomes and reduced health care costs for these patients in the long run.

This review also summarized risk factors associated with different HbA~1c~ trajectories. Several demographic, disease‐related, family‐related, and psychosocial variables have been reported among patients with type 1 diabetes. Most of the factors identified were consistent with previous studies that analysed average HbA~1c~ levels[31](#dmrr3015-bib-0031){ref-type="ref"}, [32](#dmrr3015-bib-0032){ref-type="ref"}, [33](#dmrr3015-bib-0033){ref-type="ref"}, [34](#dmrr3015-bib-0034){ref-type="ref"}, [35](#dmrr3015-bib-0035){ref-type="ref"}, [36](#dmrr3015-bib-0036){ref-type="ref"}, [37](#dmrr3015-bib-0037){ref-type="ref"}, [38](#dmrr3015-bib-0038){ref-type="ref"} and included older age, female gender, ethnic minority status, longer diabetes duration, lower glucose monitoring frequency, fewer or missed clinical appointments, and insulin delivery via injection versus insulin pump as associated with poorer HbA~1c~ trajectories. Associations with several family environment and psychosocial variables reported in cross‐sectional studies[7](#dmrr3015-bib-0007){ref-type="ref"}, [33](#dmrr3015-bib-0033){ref-type="ref"}, [39](#dmrr3015-bib-0039){ref-type="ref"}, [40](#dmrr3015-bib-0040){ref-type="ref"}, [41](#dmrr3015-bib-0041){ref-type="ref"}, [42](#dmrr3015-bib-0042){ref-type="ref"}, [43](#dmrr3015-bib-0043){ref-type="ref"} were also demonstrated in the longitudinal trajectory studies. However, we also noticed that 4 studies reported nonsignificant associations of poor HbA~1c~ trajectories and some of the variables mentioned above[20](#dmrr3015-bib-0020){ref-type="ref"}, [30](#dmrr3015-bib-0030){ref-type="ref"}, [44](#dmrr3015-bib-0044){ref-type="ref"}, [45](#dmrr3015-bib-0045){ref-type="ref"} including age, gender, ethnicity, disease duration, clinical appointment, insulin treatment, and self‐control, although the direction of association effect was consistent with other studies. This nonsignificance in results may be due to the differences in study population and statistical analysis. The sample sizes for the studies conducted by Rohan et al, Marshall et al, and Viner et al were relatively small; thus, the results may have been attenuated when comparing among multiple groups.[20](#dmrr3015-bib-0020){ref-type="ref"}, [30](#dmrr3015-bib-0030){ref-type="ref"}, [44](#dmrr3015-bib-0044){ref-type="ref"} The study conducted by Schwandt et al only compared trajectories with similar initial HbA~1c~ but different trends, which may also have led to smaller differences between groups.[45](#dmrr3015-bib-0045){ref-type="ref"} Our review also highlights some associations that had not been reported in studies using average HbA~1c~ levels, including college entrance and peer conflict. Helgeson et al reported that individuals in the poorer control group were characterized by higher peer conflict; Monaghan et al reported that although glycaemic control was relatively stable upon college entry, 31% of students had continuously poor glycaemic control during the follow‐up period, suggesting the need for increased care during the transition from high school to college among these students.

It is worth noting that some factors influencing the HbA~1c~ trajectories were only studied in type 1 diabetes but not in type 2 diabetes, including family environment, autonomy and self‐control, peer conflict, and college entry. These factors were also significantly associated with glycaemic control patterns. As onset of disease in type 1 diabetes is predominantly during childhood and adolescence, it is logical that control may be dependent on family and social support. In addition, this is also a period of development and emotional maturation, which in itself is stressful without additional burdening by the responsibilities of diabetes management. Thus, interventions to improve diabetes management in patients with type 1 diabetes might need a comprehensive consideration of all these aspects.

For studies on patients with type 2 diabetes, the factors investigated in association with HbA~1c~ trajectories were mainly demographic or disease related. Younger age, ethnic minority status, lower educational level, longer diabetes duration, higher baseline HbA~1c~, poorer lipid profiles, and higher baseline microvascular complications were reported to be associated with poorer HbA~1c~ trajectories, which were consistent with findings from previous analysis.[46](#dmrr3015-bib-0046){ref-type="ref"}, [47](#dmrr3015-bib-0047){ref-type="ref"}, [48](#dmrr3015-bib-0048){ref-type="ref"}, [49](#dmrr3015-bib-0049){ref-type="ref"} However, inconsistent with previous studies that observed increasing HbA~1c~ levels after incident co‐rmorbidities,[50](#dmrr3015-bib-0050){ref-type="ref"}, [51](#dmrr3015-bib-0051){ref-type="ref"}, [52](#dmrr3015-bib-0052){ref-type="ref"} Bayliss et al reported that patients\' HbA~1c~ trajectories did not change after incident co‐morbidities.[28](#dmrr3015-bib-0028){ref-type="ref"} It is possible that incident co‐morbidities had no significant influence on group trajectories because of the already high co‐morbid burden in these patients, with patients having 4 to 5 co‐morbid conditions at baseline. We also observed that inconsistent results were reported for the association between BMI and poorer HbA~1c~ trajectories, with Chang et al[24](#dmrr3015-bib-0024){ref-type="ref"} reporting that low BMI was associated with worse trajectories while Walraven et al,[26](#dmrr3015-bib-0026){ref-type="ref"} Laiteerapong et al,[25](#dmrr3015-bib-0025){ref-type="ref"} and Luo et al[27](#dmrr3015-bib-0027){ref-type="ref"} reported the opposite associations. This inconsistency might be due to differences in study population, as the study by Chang et al was conducted among patients with 10‐year diabetes duration while the other 3 studies were conducted among patients with newly diagnosed diabetes or patients with an average 4.5 years of diabetes. Obesity was an important risk factor for diabetes and glycaemic control[53](#dmrr3015-bib-0053){ref-type="ref"}; however, persistent hyperglycaemia may lead to reduction in weight due to osmotic diuresis and muscle breakdown with excessive gluconeogenesis from amino acid, which might explain the result for the Chang et al study. For outcomes, poorer HbA~1c~ trajectories were found to be associated with incident microvascular events and mortality, which was independent of average HbA~1c~ levels during follow‐up[25](#dmrr3015-bib-0025){ref-type="ref"} or baseline HbA~1c~ level.[27](#dmrr3015-bib-0027){ref-type="ref"} Numerous studies have reported the association between elevated HbA~1c~ level and increased risk of diabetes‐related complications and death,[2](#dmrr3015-bib-0002){ref-type="ref"}, [3](#dmrr3015-bib-0003){ref-type="ref"}, [54](#dmrr3015-bib-0054){ref-type="ref"} and this finding further suggests that patterns of HbA~1c~ might be an independent risk factor for diabetes‐related outcomes and emphasizes the importance of maintaining good glycaemic control over time.

This review has several limitations. Firstly, this review was only based on a qualitative comparison of studies. We are not aware of any current established method to combine results from multiple‐group--based trajectory models quantitatively, given the heterogeneity between studies; thus, we could not combine studies to have estimates of effect sizes of various risk factors on glycaemic control trajectories. Also, since trajectory analysis is a relatively new method applied to HbA~1c~ analysis, the number of articles available is limited. However, the current findings provide important information in terms of statistical methods and subgroup characteristics and will be useful for future research. Lastly, this review may be restricted by the selected databases, and studies published in some local journals and grey literature may have been omitted. Future studies searching on more databases may be beneficial to get a more comprehensive view of HbA~1c~ trajectory analysis.

In summary, group‐based trajectory analysis identifies subgroups of patients with different natural history of disease. These groups have different characteristics in terms of sociodemographic and disease‐related factors. For instance, transition into adulthood[55](#dmrr3015-bib-0055){ref-type="ref"} and college enrolment[22](#dmrr3015-bib-0022){ref-type="ref"} have been found to represent vulnerable periods when patients will transition into a period of poor glycaemic control. They also have different outcomes. The groups are finite in number, and many seem to be common across populations studied, suggesting that the pattern of heterogeneity is generalizable to multiple different populations. A better understanding of the psychosocial and biological factors underlying the progression of disease in these groups could lead to the development of targeted strategies to improve outcomes in these patients.
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